The Global Ovarian Cancer Research Consortium and its inaugural AI Accelerator Grant have been making waves across health, science, and business media, reflecting widespread interest in what this work could mean for patients. The $1 million global research grant, plus an additional $1 million in compute support from Microsoft’s AI for Good Lab, will fund … Continued
Written by Chad Ramsey, Vice President, Policy February brought meaningful progress in Washington. From major legislative wins to the start of a new appropriations cycle, advocates are already helping shape the policy landscape for ovarian and gynecologic cancer patients in 2026 and beyond. State-Level Momentum: Biomarker Progress Continues Momentum is building across the country to … Continued
Recognizing Advances in Ovarian Cancer Research and Immunotherapy Ovarian Cancer Research Alliance (OCRA) announced today the winners of two prizes recognizing exceptional accomplishments in ovarian cancer research. David Huntsman, MD, FRCPC, FCCMG, was awarded the 2025 Rosalind Franklin Prize for Excellence in Ovarian Cancer Research for his findings that have profoundly impacted the treatment of … Continued
Watch a replay of this webinar to learn about gynecologic clear cell carcinoma research, treatment, and survivorship. Ovarian Cancer Research Alliance (OCRA) presented an Ask the Experts webinar focused on gynecologic clear cell carcinoma, a rare subtype of gynecologic cancer, on March 25, 2026. This live, interactive webinar featured gynecologic oncologist Aaron Praiss, MD, who discussed current research, treatment … Continued
$1 million global research award, plus an additional $1 million in compute support, advances AI-driven efforts to personalize ovarian cancer care The Global Ovarian Cancer Research Consortium today awarded its inaugural AI Accelerator Grant to an international team of researchers to examine whether artificial intelligence (AI) can improve how survival and treatment response are predicted … Continued
The U.S. Food and Drug Administration (FDA) has approved the first immunotherapy regimen shown to extend survival in a subset of ovarian cancer patients. The FDA authorized Keytruda (pembrolizumab), made by Merck, in combination with chemotherapy, for PD-L1–positive, platinum-resistant epithelial ovarian, fallopian tube, and primary peritoneal cancers. Keytruda plus weekly Taxol (paclitaxel), with or without … Continued
Ovarian Cancer Research Alliance (OCRA) has announced a collaboration with OPERATION WIPE OUT, an initiative that has demonstrated meaningful success reducing cervical cancer risk in Alabama through prevention-focused education and access to care. Drawing on this proven public-health framework, OCRA will adapt and expand the model nationwide—bringing practical, evidence-based cervical cancer prevention strategies to communities … Continued
Ovarian Cancer Research Alliance (OCRA) has expanded its free, online support offerings with several new weekly sessions for individuals diagnosed with gynecologic cancers, as well as caregivers and family members. These include cervical, vaginal, and vulvar cancer support, caregiver grief support, Spanish-language sessions, and creative wellness programs. OCRA’s support sessions are facilitated by oncology social work professionals. … Continued
NEW YORK, NY — [February 5, 2026] — Ovarian Cancer Research Alliance (OCRA) has announced a collaboration with OPERATION WIPE OUT, an initiative that has demonstrated meaningful success reducing cervical cancer risk in Alabama through prevention-focused education and access to care. Drawing on this proven public-health framework, OCRA will adapt and expand the model nationwide—bringing practical, evidence-based … Continued
Written by Chad Ramsey, OCRA’s Vice President, Policy OCRA’s Advocate Leader Program Reaches Record Size in 2026 January marked a major milestone for Ovarian Cancer Research Alliance’s (OCRA) advocacy community. OCRA trained 94 new advocates to join our Advocate Leaders program, bringing our total to 227 advocates across 44 states and Washington, DC. This is … Continued
A new study published February 2 in JAMA Network Open provides the clearest evidence to date that opportunistic salpingectomy—the removal of the fallopian tubes during another gynecologic surgery—can dramatically reduce the risk of ovarian cancer. Led by a B.C.-based international collaboration known as the Ovarian Cancer Observatory, the study found that people who underwent opportunistic … Continued
Watch Now: Ask the Experts Webinar on Gynecologic Sarcoma On January 28, 2026, Ovarian Cancer Research Alliance (OCRA) hosted a live Ask the Experts: Gynecologic Sarcoma webinar with Matthew Hemming, MD, PhD. Moderated by Liza Lundgren, LCSW, OCRA’s Director of Education, this free session featured a live discussion and audience Q&A focused on gynecologic sarcoma research, … Continued
Get email updates about research news, action alerts, and ways to join the fight.
Our website uses cookies to ensure you get the best experience. By continuing to use this website, you indicate that you have read and agree to our Terms of Use and Privacy Policy.
